Distinguished in Head and Neck Squamous Cell Carcinoma (HNSCC)

Dr. Jonathan J. Beitler

Radiation Oncology | Aerospace Medicine | Radiology
1365 Clifton Rd Ne, Department Of Radiation Oncology, 
Atlanta, GA 
Clinical Trials:Currently Recruiting for 1 Trial
Distinguished in Head and Neck Squamous Cell Carcinoma (HNSCC)
1365 Clifton Rd Ne, Department Of Radiation Oncology, 
Atlanta, GA 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Jonathan Beitler is a Radiation Oncologist and an Aerospace Medicine provider in Atlanta, Georgia. Dr. Beitler is rated as a Distinguished provider by MediFind in the treatment of Head and Neck Squamous Cell Carcinoma (HNSCC). His top areas of expertise are Laryngeal Cancer, Throat Cancer, Head and Neck Squamous Cell Carcinoma (HNSCC), Glossectomy, and Tissue Biopsy.

His clinical research consists of co-authoring 156 peer reviewed articles and participating in 8 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, he has co-authored 34 articles and participated in 5 clinical trials in the study of Head and Neck Squamous Cell Carcinoma (HNSCC).

Specialties
Radiation Oncology
Aerospace Medicine
Radiology
Licenses
Aerospace Medicine in NY
Languages Spoken
English
Gender
Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Anthem
  • EPO
  • HMO
  • POS
  • PPO
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D

Locations

1365 Clifton Rd Ne, Department Of Radiation Oncology, Atlanta, GA 30322

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

8 Clinical Trials

Randomized Phase II/III Trial of Adjuvant Radiation Therapy With Cisplatin, Docetaxel-Cetuximab, or Cisplatin-Atezolizumab in Pathologic High-Risk Squamous Cell Cancer of the Head and Neck
Randomized Phase II/III Trial of Adjuvant Radiation Therapy With Cisplatin, Docetaxel-Cetuximab, or Cisplatin-Atezolizumab in Pathologic High-Risk Squamous Cell Cancer of the Head and Neck
Enrollment Status: Recruiting
Publish Date: October 14, 2025
Intervention Type: Procedure, Drug, Other, Radiation, Biological
Study Drugs: Atezolizumab, Cetuximab, Cisplatin, Docetaxel
Study Phase: Phase 2/Phase 3
A Randomized Phase II Trial for Patients With p16 Positive, Non-Smoking Associated, Locoregionally Advanced Oropharyngeal Cancer
A Randomized Phase II Trial for Patients With p16 Positive, Non-Smoking Associated, Locoregionally Advanced Oropharyngeal Cancer
Enrollment Status: Completed
Publish Date: October 09, 2025
Intervention Type: Drug, Radiation
Study Drug: Cisplatin
Study Phase: Phase 2
A Randomized Phase II/III Trial of De-Intensified Radiation Therapy for Patients With Early-Stage, P16-Positive, Non-Smoking Associated Oropharyngeal Cancer
A Randomized Phase II/III Trial of De-Intensified Radiation Therapy for Patients With Early-Stage, P16-Positive, Non-Smoking Associated Oropharyngeal Cancer
Enrollment Status: Active_not_recruiting
Publish Date: October 09, 2025
Intervention Type: Other, Procedure, Drug, Biological, Radiation
Study Drugs: Cisplatin, Nivolumab
Study Phase: Phase 2/Phase 3
Randomized Phase II/III Trial of Radiotherapy With Concurrent MEDI4736 (Durvalumab) vs. Radiotherapy With Concurrent Cetuximab in Patients With Locoregionally Advanced Head and Neck Cancer With a Contraindication to Cisplatin
Randomized Phase II/III Trial of Radiotherapy With Concurrent MEDI4736 (Durvalumab) vs. Radiotherapy With Concurrent Cetuximab in Patients With Locoregionally Advanced Head and Neck Cancer With a Contraindication to Cisplatin
Enrollment Status: Completed
Publish Date: September 23, 2025
Intervention Type: Other, Biological, Radiation
Study Drugs: Cetuximab, Durvalumab
Study Phase: Phase 2/Phase 3
A Phase III Study of Postoperative Radiation Therapy (IMRT) +/- Cetuximab for Locally-Advanced Resected Head and Neck Cancer
A Phase III Study of Postoperative Radiation Therapy (IMRT) +/- Cetuximab for Locally-Advanced Resected Head and Neck Cancer
Enrollment Status: Active_not_recruiting
Publish Date: July 20, 2025
Intervention Type: Biological, Radiation
Study Drug: Cetuximab
Study Phase: Phase 3
A Randomized Phase II/Phase III Study of Adjuvant Concurrent Radiation and Chemotherapy Versus Radiation Alone in Resected High-Risk Malignant Salivary Gland Tumors
A Randomized Phase II/Phase III Study of Adjuvant Concurrent Radiation and Chemotherapy Versus Radiation Alone in Resected High-Risk Malignant Salivary Gland Tumors
Enrollment Status: Active_not_recruiting
Publish Date: February 13, 2025
Intervention Type: Drug, Radiation
Study Drug: Cisplatin
Study Phase: Phase 2
Randomized Phase II and Phase III Studies of Individualized Treatment for Nasopharyngeal Carcinoma Based on Biomarker Epstein Barr Virus (EBV) Deoxyribonucleic Acid (DNA)
Randomized Phase II and Phase III Studies of Individualized Treatment for Nasopharyngeal Carcinoma Based on Biomarker Epstein Barr Virus (EBV) Deoxyribonucleic Acid (DNA)
Enrollment Status: Active_not_recruiting
Publish Date: November 06, 2024
Intervention Type: Other, Drug, Radiation
Study Drugs: Cisplatin, Fluorouracil, Gemcitabine Hydrochloride, Paclitaxel
Study Phase: Phase 2/Phase 3
TRYHARD: A Phase II, Randomized, Double Blind, Placebo-Controlled Study of Lapatinib (Tykerb®) for Non-HPV Locally Advanced Head and Neck Cancer With Concurrent Chemoradiation
TRYHARD: A Phase II, Randomized, Double Blind, Placebo-Controlled Study of Lapatinib (Tykerb®) for Non-HPV Locally Advanced Head and Neck Cancer With Concurrent Chemoradiation
Enrollment Status: Completed
Publish Date: October 17, 2023
Intervention Type: Drug, Radiation
Study Drugs: Cisplatin, Lapatinib
Study Phase: Phase 2
View 7 Less Clinical Trials

156 Total Publications

Head and Neck Cancer Salvage Surgery in the Era of Immunotherapy and Beyond: A Review.
Head and Neck Cancer Salvage Surgery in the Era of Immunotherapy and Beyond: A Review.
Journal: JAMA otolaryngology-- head & neck surgery
Published: October 02, 2025
Similar Doctors
James E. Bates
Distinguished in Head and Neck Squamous Cell Carcinoma (HNSCC)
Dr. James E. Bates
Radiation Oncology
Distinguished in Head and Neck Squamous Cell Carcinoma (HNSCC)
Dr. James E. Bates
Radiation Oncology

Emory Proton Therapy Center

615 Peachtree Street Northeast, 
Atlanta, GA 
 (3.6 miles away)
833-377-6866
Languages Spoken:
English
See accepted insurances
Offers Telehealth

James Bates is a Radiation Oncologist in Atlanta, Georgia. Dr. Bates is rated as an Advanced provider by MediFind in the treatment of Head and Neck Squamous Cell Carcinoma (HNSCC). His top areas of expertise are Throat Cancer, Head and Neck Squamous Cell Carcinoma (HNSCC), Bone Tumor, and Laryngeal Cancer.

Mark W. Mcdonald
Advanced in Head and Neck Squamous Cell Carcinoma (HNSCC)
Dr. Mark W. Mcdonald
Radiation Oncology
Advanced in Head and Neck Squamous Cell Carcinoma (HNSCC)
Dr. Mark W. Mcdonald
Radiation Oncology

Emory Proton Therapy Center

615 Peachtree Street Northeast, 
Atlanta, GA 
 (3.6 miles away)
833-377-6866
Experience:
21+ years
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Mark Mcdonald is a Radiation Oncologist in Atlanta, Georgia. Dr. Mcdonald has been practicing medicine for over 21 years and is rated as a Distinguished provider by MediFind in the treatment of Head and Neck Squamous Cell Carcinoma (HNSCC). His top areas of expertise are Adenoid Cystic Carcinoma, Laryngeal Cancer, Sinus Cancer, and Pancreatic Cancer.

Experienced in Head and Neck Squamous Cell Carcinoma (HNSCC)
Dr. Walter J. Curran
Radiation Oncology | Radiology
Experienced in Head and Neck Squamous Cell Carcinoma (HNSCC)
Dr. Walter J. Curran
Radiation Oncology | Radiology
1365 Clifton Rd NE, Suite #1354, 
Atlanta, GA 
 (0.1 miles away)
404-778-5323
Languages Spoken:
English
See accepted insurances

Walter Curran is a Radiation Oncologist and a Radiologist in Atlanta, Georgia. Dr. Curran is rated as an Advanced provider by MediFind in the treatment of Head and Neck Squamous Cell Carcinoma (HNSCC). His top areas of expertise are Brain Tumor, Small Cell Lung Cancer (SCLC), Glioma, and Lung Cancer.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Beitler's expertise for a condition
ConditionClose
View All 37 Experienced Conditions
Want to save this doctor for later?
Sign Up
Is this your doctor?
Find A Second Opinion
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile